Pasar al contenido principal

REGULACION CANNABINERGICA DE LOS CIRCUITOS HABENULARES: IMPACTO EN LA PATOFISIOLOGIA EMOCIONAL

PID2021-125763NB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DEL PAIS VASCO EUSKAL HERRIKO UNIBERTSITATEA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Potentiation of mitochondrial function by mitoDREADD-Gs reverses pharmacological and neurodegenerative cognitive impairment in mice

  • Pagano Zottola, Antonio C.
  • Martín-Jiménez, Rebeca
  • Lavanco, Gianluca
  • Hamel-Côté, Geneviève
  • Ramon-Duaso, Carla
  • Rodrigues, Rui S.
  • Mariani, Yamuna
  • Khan, Mehtab
  • Drago, Filippo
  • Jean, Stephanie
  • Río, Itziar Bonilla-Del
  • Jimenez-Blasco, Daniel
  • Egaña-Huguet, Jon
  • Eraso-Pichot, Abel
  • Beriain, Sandra
  • Cannich, Astrid
  • Vidal-Palencia, Laura
  • Infantino, Rosmara
  • Julio-Kalajzić, Francisca
  • Gisquet, Doriane
  • Goncalves, Ania
  • Al-Younis, Inas
  • Baussan, Yann
  • Duvezin-Caubet, Stephane
  • Devin, Anne
  • Soria-Gomez, Edgar
  • Puente, Nagore
  • Bolaños, Juan P.
  • Grandes, Pedro
  • Pouvreau, Sandrine
  • Busquets-Garcia, Arnau
  • Marsicano, Giovanni
  • Bellocchio, Luigi
  • Hebert-Chatelain, Etienne
Many brain disorders involve mitochondrial alterations, but owing to the lack of suitable tools, the causal role of mitochondrial dysfunction in pathophysiological processes is difficult to establish. Heterotrimeric guanine nucleotide-binding (G) proteins are key regulators of cell functions, and they can be found within mitochondria. Therefore, we reasoned that the activation of stimulatory mitochondrial G proteins (Gs) could rapidly promote the activity of the organelle and possibly compensate for bioenergetic dysfunction. Here, we show that a mitochondria-targeted recombinant designer receptor exclusively activated by designer drugs (mitoDREADD-Gs) can acutely trigger intramitochondrial signaling to increase mitochondrial membrane potential and oxygen consumption. In vivo activation of mitoDREADD-Gs abolished memory alterations in cannabinoid-treated mice and in two mouse models of Alzheimer's disease and frontotemporal dementia. Thus, mitoDREADD-Gs enables the establishment of causal relationships between mitochondria and biological or disease-related processes and represents an innovative potential therapeutic approach for disorders associated with mitochondrial impairment., This work was funded by the Natural Sciences and Engineering Research Council of Canada (grant number RGPIN-2015-05880 to E.H.-C.), Canadian Health Research Institute (grant number 156238 to E.H.-C. and L.B.), Canada Research Chair program (to E.H.-C.) and ResearchNB (to E.H.-C.). This work was also supported by Inserm (to G.M. and L.B.); EU–FP7 (PAINCAGE, HEALTH-603191, to G.M.); the European Research Council (Endofood, ERC–2010–StG–260515; CannaPreg, ERC-2014-PoC-640923; Micabra, ERC-2017-AdG-786467, to G.M.); Fondation pour la Recherche Medicale (DRM20101220445 to G.M.; ARF20140129235 to L.B.); the Human Frontiers Science Program (to G.M.); Region Aquitaine (to G.M.); French State/Agence Nationale de la Recherche (LABEX BRAIN ANR-10-LABX-43 and ANR-23-ce14-0004-03 to G.M., ANR-19-CE14-0039 to L.B., ERA-Net Neuron CanShank ANR-21-NEU2-0001-04 to G.M., CaMeLS ANR-23-CE16-0022-01 to G.M., Hippobese ANR-23-CE14-0004-03 to G.M.); Region Nouvelle Aquitaine (APP ESR NAq 2020 to G.M.); and the French government in the framework of the University of Bordeaux’s IdEx ‘Investments for the Future—France 2030’ program / GPR BRAIN_2030 (to G.M. and L.B.). E.S.-G. was funded by MICIU/AEI (PGC2018-093990-A-I00 and PID2021-125763NB-I00). J.P.B. was funded by MICIU/AEI (PID2022-138813OB-I00 /10.13039/501100011033 and FEDER, UE), the Instituto de Salud Carlos III (CB16/10/00282) and the European Union’s Horizon Europe research and innovation programme under MSCA Doctoral Networks 2021 (101072759, FuEl ThE bRaiN In healtThY aging and age-related diseases (ETERNITY). G.M., A.B.-G. and J.P.B. are recipients of a grant from la Caixa Foundation (agreement LCF/PR/HR23/52430016). A.B.-G., L.P-V. and C.R.D. received funding from the DIUE de la Generalitat de Catalunya (SGR 00022, 2023 FI-3 00034), from the H2020 Excellent Science—European Research Council (948217) and the Ministry of Economy and Competitiveness (RTI2018-093667-A-100; PID2021-122795OB-I00). S.P. was funded by the European Union’s Horizon 2020 research and innovation programme under Marie Skłodowska-Curie grant agreement No. 676,144 (Synaptic Dysfunction in Alzheimer's Disease, SyDAD). Grant PID2019-107548RB-I00 funded by MICIU/AEI/10.13039/501100011033 (to P.G.); The Basque Government (grant number IT1620-22 to P.G.); and grant RD21/0009/0006 funded by Instituto de Salud Carlos III (ISCIII) and by the European Union NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia (MRR), ISCIII-Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS)-Red de Investigación en Atención Primaria de Adicciones (RIAPAd) (to P.G.). G.H.-C. was supported by a fellowship from New Brunswick Health Research Foundation. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript., Peer reviewed